Cutaneous malignant melanoma remains a therapeutic challenge, and patients with advanced disease have limited survival.
Photodynamic therapy (
PDT) has been successfully used to treat many
malignancies, and it may show promise as an antimelanoma modality. However, high
melanin levels in
melanomas can adversely affect
PDT effectiveness. Herein the extent of
melanin contribution to
melanoma resistance to
PDT was investigated in a set of
melanoma cell lines that markedly differ in the levels of pigmentation; 3 new bacteriochlorins successfully overcame the resistance. Cell killing studies determined that bacteriochlorins are superior at (LD(50) approximately 0.1 microM) when compared with controls such as the FDA-approved
Photofrin (LD(50) approximately 10 microM) and clinically tested
LuTex (LD(50) approximately 1 microM). The
melanin content affects
PDT effectiveness, but the degree of reduction is significantly lower for bacteriochlorins than for
Photofrin. Microscopy reveals that the least effective
bacteriochlorin localizes predominantly in lysosomes, while the most effective one preferentially accumulates in mitochondria. Interestingly all bacteriochlorins accumulate in melanosomes, and subsequent illumination leads to melanosomal damage shown by electron microscopy.
Fluorescent probes show that the most effective
bacteriochlorin produces significantly higher levels of
hydroxyl radicals, and this is consistent with the redox properties suggested by molecular-orbital calculations. The best in vitro performing
bacteriochlorin was tested in vivo in a mouse
melanoma model using spectrally resolved fluorescence imaging and provided significant survival advantage with 20% of cures (P<0.01).